32 results about "Respirovirus" patented technology

The invention belongs to the technical fields of biochips and diagnostic reagents, and discloses a method for detecting various respiratory viruses, and primers and probes thereof. In the invention, nucleotide sequences of 14 respiratory viruses, namely adenovirus, human metapneumovirus, influenza virus A, influenza virus B, respiratory syncytial virus, bocavirus, rhinovirus, coronavirus (HKU1, NL63 and SARS), and parainfluenza virus (type I, type II, type III and type IV) are analyzed, and corresponding reverse transcription primers, PCR primers and specific probes are designed. Specific gene segments are amplified by reverse transcription and multiple asymmetric PCR methods; a fluorescence-coded microsphere group coupled with the virus specific probes and the PCR amplification product are incubated and hybridized by liquid phase chip technology; and finally the Bio-PlexTM200 is used for detection. The detection method has the advantages of high flux, high specificity and sensitivity, stable results and good repeatability, the detection method is easy to operate, and the detection speed is high.

The invention discloses a Multiplex PCR detection kit for nucleic acids of twelve respiratory viruses. The kit includes primers for amplifying the specific gene loci of the following twelve respiratory viruses: influenza A virus (Inf A), influenza A H1N1 (2009), influenza A H3N2, human parainfluenza virus (HPIV1), human parainfluenza virus (HPIV2), human parainfluenza virus (HPIV3), human parainfluenza virus (HPIV4), human metapneumovirus (hMPV), respiratory adenovirus (AdV), respiratory syncytial virus (RSV), bocavirus (BoV) and coronavirus (CoV). The kit allows multiplex detection, has high sensitivity and is convenient and quick to use. Specific primer sequences ensure reliability of detection results. A detection method is simple in operation, save time and labor intensity, has high detection throughput, is low in cost of reagent and consumable, and can directly detect the nucleic acids extracted from a respiratory pathogen sample, is low in requirement on detection platform and operation technology, and can be widely promoted in common detection.

The present invention relates to methods of detection, as well as assays, reagents and kits for the specific detection of 15 clinically important respiratory viruses including influenza A and B viruses, human respiratory syncytial viruses, human metapneumoviruses, human enteroviruses, all serotypes of rhinoviruses, 7 serotypes of adenoviruses, parainfluenza viruses types 1, 2, 3, and 4, as well as coronaviruses NL, 229E, OC43, and SARS-CoV. The present invention allows for the detection of each of these respiratory viruses in a single assay.

The invention discloses a high-flux non-diagnostic detection method for 13 respiratory viruses based on a novel suspension chip technology. Aiming at the specificity gene sequences of 13 pieces or types of respiratory viruses, such as influenza viruses A and B, auxiliary influenza viruses 1 and 3, coronavirus SARS-CoV and CoV-NL63, respiratory syncytial viruses A and B, adenoviruses B and E, a rhinovirus, a human metapneumovirus and an enterovirus, 13 pairs of primers and corresponding specificity probes are designed; by multiple polymerase chain reaction (PCR) amplification and TSPE reaction, X-TAG nucleic acid fragment and biotin are respectively marked with corresponding gene fragments; the marked fragments are combined with corresponding encoded micro balls; and a suspension chip scanner is used for performing detection. The high-flux non-diagnostic detection method can accurately detect 13 respiratory viruses and subtypes of the 13 respiratory viruses; the probes do not generate cross reaction; the specificity is high; and the sensitivity is high. A high-flux, quick and accurate technical platform is capable of simultaneously detecting various respiratory viruses; technical equipment is supplied to the detection of pathogens of sudden respiratory tract infectious diseases; and information can be timely supplied to the handling of infectious disease epidemic situation burst.

The invention relates to a medicine compound with interferon. Wherein, said compound can be used to prepare the medicine that prevents and resists virus infection of respiratory tract. Said compound contains interferon and other auxiliary materials. Wherein, said interferon can be alpha2b, alpha1b, beta, Omega, k, lambada, epsilon and other I type; said auxiliary materials contains protector and baffle solution; and said interferon can be recombined interferon or / and the ones made by other methods; the auxiliary materials can be acidic buffer, protein, manna sugar, polyose, and benzoic alcohol to realize baffle, stabilize and corrosion-resistant functions.

The invention relates to a kind of natural medicine of broad spectrum antibiotic. At present, the broad spectrum antibiotic medicine with high effect and safety is at shortage all round the world. The invention is intended to extract laminarinsulphate or sulphonic acid sugar ester or sulphosalts from plant chickweed or other chickweed plant with two resin adsorption methods or a water extraction and alcohol precipition method. The spectrum antibiotic in the invention is distributed under 50,000 in the formula weight formed by carbon glycosidic bond and / or oxide glycosidic bond with phenol, especially the total flavones comprising apigenin. However, the invention mainly acts as total phenolic glycoside with the formula weight under 4,000. Besides, the invention can form brownish compound with the total flavones comprising apigenin and the glycosidic ingredients without sulfur element, so as to be applied as broad spectrum antibiotic drug. Therefore, the compound in the invention can be applied to cure ADIS virus, hepatitis virus, influenza virus and parainfluenza virus comprising SARS, adenovirus, verruca acuminate virus, enterovirus, mumps virus, herpes simplex virus, herpes zoster virus and varicella. No toxic effect has been found in the application. What is more, the invention can be made into 10 sorts of formulation, disinfector and health-improving products.

The invention discloses LAMP (loop-mediated isothermal amplification) primer combination for detecting six respiratory viruses, and the application thereof. The primer combination provided by the invention consists of 36 DNA molecules as shown in the sequence 1 to the sequence 36. The primer combination can be used for detecting whether a to-be-detected virus is influenza A virus subtype H1N1, influenza A virus subtype H3N2, avian influenza virus subtype H5N1, avian influenza virus subtype H7N9, influenza B virus or human adenovirus, and can be used for detecting whether a to-be-detected sample contains influenza A virus subtype H1N1 and / or influenza A virus subtype H3N2 and / or avian influenza virus subtype H5N1 and / or avian influenza virus subtype H7N9 and / or influenza B virus and / or human adenovirus. The primer combination provided by the invention is used for detecting six respiratory viruses, has high specificity and high sensitivity, and can realize simple, convenient, rapid and accurate detection. A great promotional value is achieved.

An immunomodulatory compound is administered to a patient having, or at risk of a respiratory viral infection.

A biochip for detecting the respirovirus features that the conservative probe is designed by biologic calculation and analysis, the gene detection chip is prepared, and a technique platform able to sensitively, specifically and quickly detect various respiroviruses at the same time is created by crossing and scan analyzing.

The present invention discloses a medicine composition for curing avian respirovirus and bacterial infection and its preparation method. Said medicine composition is characterized by that every 1500 ml of liquid medicine contains 350-450 g of isatis root, 150-250 g of coptis root, 225-275 g of lonicera flower, 270-330 g of sculellaria root, 180-220 g of bushy sophora root, 135-165 g of licorice, 225-250 ml of 95% ethyl alcohol, 3 g of sodium bisulfite and the rest is distilled water. Besides, said invention also provides the concrete steps of its preparation method.

The invention discloses a primer combination and plasmid for simultaneously detecting 9 kinds of respiratory tract viruses and a detection kit and belongs to the technical field of biology. The primercombination comprises primer pairs for detecting an influenza a virus, an influenza b virus, an H7 influenza virus, an NL63 corona virus, a 229E corona virus, a type 2 parainfluenza virus, Bocavirus,a respiratory syncytial virus A, a respiratory syncytial virus B and a human internal-reference GAPDH gene. The detection kit comprises a 2*multiple reverse transcription PCR reaction solution, a reverse transcription PCR enzyme mixed solution, a primer mixed solution, non-RNAase water, a magnetic bead mixed solution, a reported buffer solution, a positive control and phycoerythrin-modified streptavidin. According to the primer combination and plasmid and the detection kit, by virtue of a liquid-phase chip technology, the manufactured detection kit can be used for carrying out qualitative analysis on a variety of respiratory tract viruses simultaneously, and the sensitivity and specificity of detection reach PCR levels; and types of respiratory tract virus infections can be rapidly and accurately judged, early etiologic diagnosis and treatment on clinical respiratory tract infections are facilitated, the shortening of a treatment cycle is facilitated, the medical expense is reduced, and good social benefits are generated.

This invention discloses using SPR technology to simultaneously and qualitatively detect the presence of respiratory tract viruses-related immunological markers in a serum sample, which can be used for the diagnosis of respiratory tract infections. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of representative antigens used to detect the respective respiratory tract viruses-related immunological markers (antibodies) in blood for the diagnosis of respiratory tract infections.

The invention provides methods of preventing and / or treating infection by a respiratory virus such as respiratory syncytial virus (RSV), particularly reducing infection and / or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being exposed to a respiratory virus, has been exposed to a respiratory virus or is infected with a respiratory virus. The ISS is administered without any antigens of the respiratory virus. Administration of the ISS results in reduced incidence and / or severity of one or more symptoms of respiratory virus infection.

The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells and pharmaceutical compositions containing siRNA sequences.

At present, the whole world is a lack of clinically high-efficient and safe broad-spectrum antiviral drugs. A composite of total riboside proteosome component that is prepared from plant chickweed or another stellaria plant and extracted by two resin adsorption methods and a hydroalcohol through a hyperfiltration method, has a molecular weight of 1,000 to 100,000 and is in the form of dark brown powder is used as a safer and more high-efficient broad-spectrum antiviral natural drug. The total protein of the total riboside proteosome component takes up 15% to 25% in the chemical construction, and is made up of 17 amino acids, such as asparaginic acid, glutamic acid, serine, histidine, cystine, methionine, isoleucine and the like in proportions; the proportion of sugar comprises ribose, glucose, galactose and arabinose, and total ribonucleotide takes up 5% to 10% and comprises uracil, thymine, thymidine, guanosine, 2-chloro-adenosine. The composite can be used as a drug for treating virus diseases, such as AIDS virus, hepatitis virus, respiratory syncytial viruses like influenza virus, parainfluenza virus, adenovirus, and the like, including highlypathogenic avian influenza virus, and condyloma virus, enterovirus, mumps virus, herpes simplex virus, herpes zoster virus and varicella-zoster virus. Moreover, the composite has no toxicity, and can be made into more than 10 types of medicine preparations, health products and the like, while causing no environmental pollution in the production process.

The invention belongs to the field of pharmacy, disclosing a compound and application thereof in preparing a drug for curing viral respiratory infection. The compound comprises the following structural formula shown in a formula (I), wherein R is-CH2-CH2-, R' is linear chain or multiple-chain alkyl of C4-C14, x is 1-50, and y is 0-50. The compound has the effect of resisting respiratory system viral infection and can be used for preparing the drug for treating respiratory system viral infection.

The invention relates to the technical field of biology, in particular to a PCR (Polymerase Chain Reaction) primer group and a kit for jointly detecting various respiratory viruses. The PCR primer group comprises an influenza A virus detection primer pair, an influenza A virus H1N1 detection primer pair, an influenza A virus H3N2 detection primer pair, an influenza B virus detection primer pair, a human respiratory syncytial virus detection primer pair, a human metapneumovirus detection primer pair and a rhinovirus / enterovirus detection primer pair. The kit comprises a multiplex RT-PCR (Reverse Transcription-Polymerase Chain Reaction) reactant, and the multiplex RT-PCR reactant comprises the PCR primer group. The primer group and the kit disclosed by the invention can be used for jointly detecting and identifying seven respiratory viruses, the method is simple to operate, accurate in detection, high in sensitivity and high in specificity, the detection time is remarkably shortened, and a detection result can be obtained within 2-3 hours.

The invention discloses a biological marker for diagnosing respiratory syncytial virus infection of children. The biological marker can be used for assisting to diagnose the respiratory syncytial virus infection of the children. The invention also discloses a combination of at least two biological markers correlated with the respiratory syncytial virus infection of the children; the respiratory syncytial virus infection of the children can be combined with a bioinformatics method to use; the invention further discloses a product correlated with the biological marker.

The invention discloses an NGS primer set and a kit for respiratory RNA pathogens (flu A, flu B, syncytial virus, and new crown). The primer set consists of 594 primer sequences. The present invention specifically designs 594 primers for influenza A, influenza B, syncytial virus and novel coronavirus genomes, covering the entire viral genome, improving the detection of viruses and greatly improving the possibility of full-length detection of viral genome sequences without PCR amplification. It can quickly achieve full coverage of the viral genome.

This invention relates to the field of medicine and concerns a method for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, which envisages the use of an effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for producing the aforesaid compounds, and to pharmaceutical compositions for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, which contain an effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof. The invention solves the problem of providing a novel agent effective in the treatment of diseases caused by RNA-containing viruses belonging to the enterovirus genus, the metapneumovirus genus, the pneumovirus genus, the respirovirus genus or the alphacoronavirus genus, and DNA-containing viruses belonging to the adenovirus family and the herpesvirus family, and also effective in the prophylaxis and treatment of asthma exacerbations, chronic obstructive pulmonary disease, cystic fibrosis, conjunctivitis, gastroenteritis, hepatitis and myocarditis, and in the prophylaxis and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia or obstructive airways syndrome.

The invention relates to a kind of natural medicine of broad spectrum antibiotic. At present, the broad spectrum antibiotic medicine with high effect and safety is at shortage all round the world. The invention is intended to extract unsaturated polyoses, polyoses alcohol or phenolic compounds with the main formula weight under 4,000 and with the content of hydrosulphonyl, thioalcohol, alkene and / or alkane radicals, from plant chickweed or other chickweed plant with two resin adsorption methods or a water extraction and alcohol precipition method, especially the compound with flavonoid compound and total phenolic glycoside ingredients. Therefore, the compound in the invention can be applied to cure ADIS virus, hepatitis virus, influenza virus and parainfluenza virus comprising SARS, adenovirus, verruca acuminate virus, enterovirus, mumps virus, herpes simplex virus, herpes zoster virus and varicella. No toxic effect has been found in the application. What is more, the invention can be made into 10 sorts of formulation, disinfector and health-improving products.

The invention discloses a kit for detecting eight respiratory pathogens including novel coronavirus and application thereof. The kit comprises specific amplification primers for amplifying nine gene loci of the following eight respiratory pathogens, wherein the nine gene loci are ORF and N genes of a 2019 novel coronavirus, a hemagglutinin gene of an influenza A virus, an M protein gene of an influenza B virus, an upstream segment of a Hexon gene Loop1 of an adenovirus, a hemagglutinin-neuraminidase gene of a parainfluenza virus, an F protein gene of a respiratory syncytial virus, a VP1 capsid protein gene of a rhinovirus and a 16S rRNA gene of mycoplasma pneumoniae; and a specific amplification primer of the reference gene ACTB. According to the kit, a multiple RT-qPCR technology is adopted, highly conserved sequences of a human reference gene, a novel coronavirus SARS-CoV-2 and other seven common respiratory viruses are taken as target regions, nine groups of specific primers and probes are designed, a three-tube quadruple detection system is constructed, and higher specificity is achieved.

The invention discloses a triple TaqMan fluorescent quantitative PCR detection reagent, a kit, a detection method and application. The detection reagent comprises a specific qPCR detection primer for a novel coronavirus (SARS-CoV-2), a feline calicivirus (FCV) and an influenza A virus (IAV), and a corresponding TaqMan probe. According to the detection method, three pairs of specific primers and TaqMan probes are designed mainly aiming at SARS-CoV-2, FCV and IAV, three kinds of cat respiratory viruses can be simultaneously detected in one PCR reaction tube, the detection sensitivity can reach 1 * 10 < 1 > copies / mu L, and the detection method has excellent specificity and repeatability and can be applied to clinical detection of pets.

The invention discloses a primer combination and a method for detecting common respiratory viruses. The primer combination comprises two or more of 12 pairs of primers for detecting 15 common respiratory viruses. The detection method comprises the following steps: performing high-throughput sequencing on a captured sequence of a to-be-detected sample, and comparing the sequence with characteristic sequences of specific region nucleic acids of 15 common respiratory viruses by using a bioinformatics analysis method, so that whether the sequence of the to-be-detected sample is matched with the 15 common viruses or not can be very accurately judged. The primer combination has the advantages of high accuracy and high flux.

The invention discloses a high-flux non-diagnostic detection method for 13 respiratory viruses based on a novel suspension chip technology. Aiming at the specificity gene sequences of 13 pieces or types of respiratory viruses, such as influenza viruses A and B, auxiliary influenza viruses 1 and 3, coronavirus SARS-CoV and CoV-NL63, respiratory syncytial viruses A and B, adenoviruses B and E, a rhinovirus, a human metapneumovirus and an enterovirus, 13 pairs of primers and corresponding specificity probes are designed; by multiple polymerase chain reaction (PCR) amplification and TSPE reaction, X-TAG nucleic acid fragment and biotin are respectively marked with corresponding gene fragments; the marked fragments are combined with corresponding encoded micro balls; and a suspension chip scanner is used for performing detection. The high-flux non-diagnostic detection method can accurately detect 13 respiratory viruses and subtypes of the 13 respiratory viruses; the probes do not generate cross reaction; the specificity is high; and the sensitivity is high. A high-flux, quick and accurate technical platform is capable of simultaneously detecting various respiratory viruses; technical equipment is supplied to the detection of pathogens of sudden respiratory tract infectious diseases; and information can be timely supplied to the handling of infectious disease epidemic situation burst.

An application of Albiduoya sulfoxide and its biocompatible salts in preparing the medicines for preventing and treating the virus infection of respiratory tract, such as viral influenza, is disclosed.

The invention provides novel high-sensitivity respiratory virus nucleic acid NASBA (nucleic acid sequence based amplification) primers. A respiratory virus conservative area is selected, and a promoter sequence capable of being recognized by T7 RNA (ribose nucleic acid) polymerase is formed at the 5' terminal of one of the synthesized primers. The invention further provides a novel high-sensitivity respiratory virus nucleic acid NASBA detection method. T7 RNA polymerase promoter sequences are added to the 5' terminals of the two primers complementary to two ends of a respiratory virus RNA sequence, so that when the primers enter a circulation phase, RNA sequences [RNA(+)] consistent with a template sequence can be synthesized, RNA sequences [RNA(-)] complementary to a template RNA sequence can be synthesized, and the detection sensitivity of viral nucleic acid is greatly improved; a throat swab sample of a patient can be directly used for amplification, a reverse transcription process is not required, and the operation time is saved.

The present invention is related to detecting respiratory diseases using molecular markers as prognostic tool of the evolution of respiratory infection cases. Concretely, during the differential diagnostic of respiratory infections caused by the Syncytial Respiratory Virus and human Metapneumovirus, it will be established the expression pattern of the severity markers of IL-3, IL-33 and IL12p40. The expression pattern of the molecular markers can be defined in biological samplers using ELISA assays, flow cytometry or PCR in real time. The confirmation of the etiological agent of the infection in combination to the pattern definition of the molecular markers IL-3, IL-33 and IL12p40 will indicate a prognostic of the disease severity.